Shopping Cart 0
Cart Subtotal
USD 0

Sunesis Pharmaceuticals Inc (SNSS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.

Sunesis Pharmaceuticals Inc (SNSS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11

Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13

Equity Offering 14

Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14

Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16

Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18

Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20

Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21

Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23

Sunesis Pharma Prices Public offering of Shares for USD8 Million 25

Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For USD 43 Million 26

Asset Transactions 27

Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For USD 25 Million 27

Sunesis Pharmaceuticals Inc-Key Competitors 29

Sunesis Pharmaceuticals Inc-Key Employees 30

Sunesis Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights 32

Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33

May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results 35

Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights 36

Nov 02, 2017: Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights 38

Jul 27, 2017: Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights 40

May 08, 2017: Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights 42

Mar 09, 2017: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights 44

Corporate Communications 46

Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes 46

Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors 47

Dec 04, 2017: Sunesis Pharmaceuticals Announces Change in Leadership 48

Nov 30, 2017: Sunesis Pharmaceuticals Appoints William Quinn as CFO and Senior Vice President, Finance and Corporate Development 49

Legal and Regulatory 50

Jun 26, 2017: Sunesis Pharmaceuticals added to Russell Microcap Index 50

Product News 51

12/05/2017: Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 51

07/18/2017: Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies 52

Product Approvals 53

May 01, 2017: Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML 53

Mar 22, 2017: Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin 54

Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062 55

Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on Vosaroxin 56

Clinical Trials 57

Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sunesis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11

Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13

Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14

Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16

Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18

Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20

Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21

Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23

Sunesis Pharma Prices Public offering of Shares for USD8 Million 25

Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For USD 43 Million 26

Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For USD 25 Million 27

Sunesis Pharmaceuticals Inc, Key Competitors 29

Sunesis Pharmaceuticals Inc, Key Employees 30

Sunesis Pharmaceuticals Inc, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Sunesis Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.

Sunesis Pharmaceuticals Inc (SNSS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11

Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13

Equity Offering 14

Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14

Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16

Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18

Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20

Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21

Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23

Sunesis Pharma Prices Public offering of Shares for USD8 Million 25

Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For USD 43 Million 26

Asset Transactions 27

Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For USD 25 Million 27

Sunesis Pharmaceuticals Inc-Key Competitors 29

Sunesis Pharmaceuticals Inc-Key Employees 30

Sunesis Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights 32

Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33

May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results 35

Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights 36

Nov 02, 2017: Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights 38

Jul 27, 2017: Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights 40

May 08, 2017: Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights 42

Mar 09, 2017: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights 44

Corporate Communications 46

Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes 46

Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors 47

Dec 04, 2017: Sunesis Pharmaceuticals Announces Change in Leadership 48

Nov 30, 2017: Sunesis Pharmaceuticals Appoints William Quinn as CFO and Senior Vice President, Finance and Corporate Development 49

Legal and Regulatory 50

Jun 26, 2017: Sunesis Pharmaceuticals added to Russell Microcap Index 50

Product News 51

12/05/2017: Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 51

07/18/2017: Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies 52

Product Approvals 53

May 01, 2017: Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML 53

Mar 22, 2017: Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin 54

Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on SNS-062 55

Jan 23, 2017: Sunesis Pharmaceuticals Provides Update on Vosaroxin 56

Clinical Trials 57

Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting 57

Appendix 58

Methodology 58

About GlobalData 58

Contact Us 58

Disclaimer 58


List Of Figure

List of Figures

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sunesis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 11

Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 13

Sunesis Pharma to Raise up to USD15.5 Million in Private Placement of Shares 14

Sunesis Pharmaceuticals Raises USD20 Million in Public Offering of Shares 16

Sunesis Pharma Raises USD28 Million in Public Offering of Shares 18

Sunesis Pharma Raises USD17 Million in Public offering of Preferred Shares 20

Sunesis Pharma Raises USD9 Million in Public Offering of Shares 21

Sunesis Pharma Raises USD17 Million in Public Offering of Shares 23

Sunesis Pharma Prices Public offering of Shares for USD8 Million 25

Sunesis Pharma Completes Public Offering Of Common Stock And Warrants For USD 43 Million 26

Royalty Pharma Completes Acquisition Of Royalty Agreement For Vosaroxin From Sunesis Pharma For USD 25 Million 27

Sunesis Pharmaceuticals Inc, Key Competitors 29

Sunesis Pharmaceuticals Inc, Key Employees 30

Sunesis Pharmaceuticals Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Sunesis Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.